Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a release of voting rights as informed by the Netherlands Authority for the Financial Markets (AFM). The notification, disclosed by BlackRock, Inc., details the distribution of shares and voting rights across various BlackRock entities, highlighting a significant capital interest and voting rights in Qiagen. This announcement reflects BlackRock’s substantial indirect holdings in Qiagen, which may influence the company’s strategic direction and stakeholder interests.
The most recent analyst rating on (QGEN) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on delivering solutions that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,469,366
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.